NVS - Novartis AG

NYSE - Nasdaq Real Time Price. Currency in USD
86.64
-0.09 (-0.10%)
As of 10:58AM EST. Market open.
Stock chart is not supported by your current browser
Previous Close86.65
Open86.76
Bid86.48 x 200
Ask86.50 x 300
Day's Range86.44 - 87.29
52 Week Range69.53 - 87.29
Volume386,658
Avg. Volume1,523,417
Market Cap204.055B
Beta0.72
PE Ratio (TTM)30.87
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield2.72 (3.14%)
Ex-Dividend Date2017-03-01
1y Target EstN/A
Trade prices are not sourced from all markets
  • Vertex Pharmaceuticals to Target 90% of Cystic Fibrosis Patients
    Market Realist2 hours ago

    Vertex Pharmaceuticals to Target 90% of Cystic Fibrosis Patients

    Should Investors Be Interested in Vertex Pharmaceuticals in 2018?

  • Vertex Pharmaceuticals Has Robust Late-Stage Research Pipeline
    Market Realist3 hours ago

    Vertex Pharmaceuticals Has Robust Late-Stage Research Pipeline

    Should Investors Be Interested in Vertex Pharmaceuticals in 2018? On October 25, 2017, Vertex Pharmaceuticals (VRTX) announced positive top-line results from its open-label Phase 3 trial that evaluated Orkambi in 60 children suffering with cystic fibrosis (or CF) who have two copies of the F508del mutation. The trial reached its primary endpoint of safety, and Orkambi demonstrated improvement in secondary endpoints such as nutritional status and sweat chloride.

  • Teva Pharmaceutical: Still Focused on New Product Launches
    Market Realist3 hours ago

    Teva Pharmaceutical: Still Focused on New Product Launches

    Can Teva Pharmaceutical's Restructuring Plan Help It Recuperate? The Vanguard Total International Stock ETF (VXUS) holds 0.09% of its total portfolio in TEVA stock. Teva Pharmaceutical Industries (TEVA) has its biggest value chain in the market as the company’s core strength, which has helped it establish itself as the leading generics pharmaceutical company in the world.

  • Reuters9 hours ago

    Novartis's Kymriah wins speedy reviews in U.S., Europe

    Novartis has been granted fast-track reviews of its cell therapy Kymriah for blood cancers in the United States and Europe, the Swiss drugmaker said on Wednesday, as it seeks to expand the pool of patients eligible for the costly treatment. Kymriah, already approved for treatment of children and young adults with r/r B-cell acute lymphoblastic leukemia (ALL), will now get speedy scrutiny by the U.S. Food and Drug Administration for use against relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL) in adults, the company said in a statement. In addition, the European Medicines Agency granted an accelerated assessment for Kymriah in children and young adults with ALL.

  • How Teva Pharmaceutical Plans to Improve Financial Profile
    Market Realistyesterday

    How Teva Pharmaceutical Plans to Improve Financial Profile

    Can Teva Pharmaceutical's Restructuring Plan Help It Recuperate? As we saw in the previous part of this series, Teva Pharmaceutical Industries (TEVA) is determined to pay down a considerable amount of its debt totaling $32 billion over the next few years. The company aims to achieve financial stability through improvement in operating profits and stable cash flow generation over the next few years.

  • Novartis (NVS) Announces Acceptance of Humira BLA by the FDA
    Zacksyesterday

    Novartis (NVS) Announces Acceptance of Humira BLA by the FDA

    Novartis (NVS) Biologics License Application (BLA) for the proposed biosimilar of blockbuster drug Humira was accepted by the FDA under the 351 (k) pathway.

  • Momenta Pharmaceuticals, Inc. Continues Its Rollercoaster Ride
    Motley Fool5 days ago

    Momenta Pharmaceuticals, Inc. Continues Its Rollercoaster Ride

    At least it's on the upswing.

  • The Key Challenges Teva Pharmaceutical Is Facing
    Market Realist5 days ago

    The Key Challenges Teva Pharmaceutical Is Facing

    Can Teva Pharmaceutical's Restructuring Plan Help It Recuperate? In December 2017, Teva Pharmaceutical Industries (TEVA) announced a restructuring plan to recuperate sales. Its stock has had a bull run since the announcement, rising 44.5% since the company’s weak earnings results for fiscal 3Q17 on November 2, 2017.

  • What Analysts Recommend for Roche in January 2018
    Market Realist5 days ago

    What Analysts Recommend for Roche in January 2018

    What to Expect from Roche in 2018

  • Zelboraf Could Boost Roche’s Sales Growth in 2018
    Market Realist5 days ago

    Zelboraf Could Boost Roche’s Sales Growth in 2018

    What to Expect from Roche in 2018

  • Approval of Alecensa in Europe Could Boost Roche’s Revenue Growth
    Market Realist6 days ago

    Approval of Alecensa in Europe Could Boost Roche’s Revenue Growth

    What to Expect from Roche in 2018

  • Perjeta Could Significantly Boost Roche’s Revenue Growth in 2018
    Market Realist7 days ago

    Perjeta Could Significantly Boost Roche’s Revenue Growth in 2018

    What to Expect from Roche in 2018Recent approval

  • American City Business Journals7 days ago

    Novartis becomes latest big-name collaborator for Chapel Hill company

    On the heels of collaborations with Bristol-Myers Squibb (BMY) and Allergan (AGN), Chapel Hill-based clinical data company Target PharmaSolutions’ latest collaboration is with Novartis (NVS). Novartis will collaborate with Target on its NASH study, focused on patients with nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH).

  • Novartis Starts Trial on Psoriasis Drug Cosentyx Biosoimilar
    Zacks7 days ago

    Novartis Starts Trial on Psoriasis Drug Cosentyx Biosoimilar

    Novartis (NVS) announced the initiation of a trial on the biosimilar version of Cosentyx which will compare the drug to its proposed biosimilar for the treatment of ankylosing spondylitis.

  • Ignyta and Its Key Risks in 2018
    Market Realist7 days ago

    Ignyta and Its Key Risks in 2018

    Ignyta and Its Drug Candidates for 2018

  • Why AbbVie Wants Imbruvica to Be a Foundation Therapy in Hematologic Oncology
    Market Realist7 days ago

    Why AbbVie Wants Imbruvica to Be a Foundation Therapy in Hematologic Oncology

    In 3Q17, Imbruvica reported global revenues close to $688 million for AbbVie (ABBV). This represented a YoY (year-over-year) growth of ~37.3%. The drug reported revenues of close to $574 million in the US, which represents a YoY rise a close to 31.0%.

  • Inside Ignyta’s Financial Performance
    Market Realist7 days ago

    Inside Ignyta’s Financial Performance

    Ignyta and Its Drug Candidates for 2018

  • Ignyta’s Drug Pipeline
    Market Realist8 days ago

    Ignyta’s Drug Pipeline

    Ignyta and Its Drug Candidates for 2018

  • A Close Look at Ignyta’s Licensing Agreement
    Market Realist8 days ago

    A Close Look at Ignyta’s Licensing Agreement

    The agreement granted Ignyta exclusive global rights to develop and commercialize entrectinib. Under the license, Ignyta’s development rights are exclusive for entrectinib for the term of the agreement. The license also grants exclusive rights to Ignyta for a term of five years with respect to any product candidate that NMS might develop that has activity against the target proteins of entrectinib.

  • AbbVie Expects Peak Sales of $7 Billion for Imbruvica
    Market Realist8 days ago

    AbbVie Expects Peak Sales of $7 Billion for Imbruvica

    AbbVie (ABBV) has projected Imbruvica’s annual revenues to reach $5 billion by 2020. The drug has already changed the treatment paradigm in the second line plus CLL segment and for CLL patients with 17p deletion. AbbVie expects that in the future, nearly eight out of ten CLL patients will benefit from an Imbruvica-based therapy at one point or another.

  • Assessing Incyte’s 3Q17 Product Portfolio
    Market Realist8 days ago

    Assessing Incyte’s 3Q17 Product Portfolio

    New Insights for Incyte Corporation as of January

  • Analyst Recommendations for Ignyta and Its Peers in January 2018
    Market Realist8 days ago

    Analyst Recommendations for Ignyta and Its Peers in January 2018

    Delaware-based Ignyta (RXDX) is focused on precision medicine in oncology. It endeavors to eradicate residual disease or the source of a reoccurrence of cancer in targeted patient populations. Ignyta is pursuing an integrated therapeutic and diagnostic strategy to treat cancer patients.

  • How Was Incyte’s Revenue Stream in 3Q17?
    Market Realist8 days ago

    How Was Incyte’s Revenue Stream in 3Q17?

    As we discussed earlier, Incyte (INCY) reported revenue of $381.5 million in 3Q17, a 41.6% rise over its revenue of $269.5 million in 3Q16. This revenue growth was driven by increased demand for the drug Jakafi. The above graph shows a revenue breakup for Incyte over the last few quarters.

  • GuruFocus.com8 days ago

    5 Companies Hit 52-Week Highs

    Multiple companies have managed to reach yearly highs